GSK reports 94% response rate for Jideytro in ROS1-positive lung cancer at World Conference

GSK is moving a newly acquired lung-cancer drug, Jideytro, toward FDA review after presenting data at the World Conference on Lung Cancer.

The conference data showed a 94% response rate when Jideytro was used as first-line therapy for patients whose tumors carry the ROS1 alteration.

The results were highlighted as a strong signal for the drug's efficacy in this molecularly defined subset of non-small cell lung cancer, supporting GSK's plan to expand the indication.